Masaaki Iwatsuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Masaaki Iwatsuki has a total of 442 co-authors. Here are the top co-authors by number of shared publications:
Hideo Baba
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
37 shared publications- Hideo Baba
Institute of Pathology, University Hospital Essen, University Duisburg-Essen, Germany (D.M., H.A.B.).
37 shared publications - Yoshifumi Baba
Department of Gastrointestinal Surgery, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan
32 shared publications - Yuji Miyamoto
Department of gastroenterological surgery, Kumamoto University, Kumamoto, Japan
24 shared publications Naoya Yoshida
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
21 shared publicationsKeisuke Kosumi
Department of Gastroenterological Surgery, Graduate School of Medical Sciences, Kumamoto University, Kumamoto, Japan
20 shared publications
Latest Publications
- 20 October 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- p. 1-11
Safety and efficacy of neoadjuvant S-1 and oxaliplatin therapy for gastric cancer in the elderly: combined phase II trials of KSCC1601 and KSCC1801
Background The efficacy of neoadjuvant chemotherapy in elderly patients with locally advanced gastric cancer remains unclear. We evaluated neoadjuvant S-1 plus oxaliplatin (SOX) therapy in elderly patients using patient data from two phase II trials. Methods Patient data from KSCC1601 and KSCC1801 phase II trials were integrated. Patients were divided into an elderly group (age ≥75 years) and a non-elderly group (age p = 0.64; RFS: HR = 1.12, 95% CI 0.51–2.44, p = 0.79). Undifferentiated histology, stage III disease, and poor pathological response were associated with worse survival. Conclusions Neoadjuvant SOX therapy is feasible in selected elderly patients with locally advanced gastric cancer and yields survival comparable to those of younger patients.
- 20 October 2026
- Published by Springer Nature in International Journal of Clinical Oncology
- p. 1-11
Safety and efficacy of neoadjuvant S-1 and oxaliplatin therapy for gastric cancer in the elderly: combined phase II trials of KSCC1601 and KSCC1801
Background The efficacy of neoadjuvant chemotherapy in elderly patients with locally advanced gastric cancer remains unclear. We evaluated neoadjuvant S-1 plus oxaliplatin (SOX) therapy in elderly patients using patient data from two phase II trials. Methods Patient data from KSCC1601 and KSCC1801 phase II trials were integrated. Patients were divided into an elderly group (age ≥75 years) and a non-elderly group (age p = 0.64; RFS: HR = 1.12, 95% CI 0.51–2.44, p = 0.79). Undifferentiated histology, stage III disease, and poor pathological response were associated with worse survival. Conclusions Neoadjuvant SOX therapy is feasible in selected elderly patients with locally advanced gastric cancer and yields survival comparable to those of younger patients.
- Open Access
- 16 September 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (10) , 4047-4050
A rare case of lesser omental hernia in a male patient following total colectomy
Introduction and importance: A lesser omental hernia is a rare internal hernia in which intestinal loops become entrapped through a defect in the lesser omentum, potentially causing bowel obstruction. Its diagnosis is challenging because of nonspecific symptoms that resemble those of other gastrointestinal diseases. This report presents a case of lesser omental hernia following total colectomy. Case presentation: A 65-year-old male with a history of laparoscopic total colectomy for ulcerative colitis 4 years prior presented with acute abdominal pain and distension. Computed tomography (CT) revealed a closed-loop small-bowel obstruction, leading to emergency surgery. Intraoperatively, no adhesions were found, but nearly the entire small intestine had herniated through a small foramen in the lesser omentum, passing dorsally behind the stomach. The intestine was repositioned, and the foramen was sutured closed. The patient was discharged on postoperative day 15, with no recurrence observed at the 6-month follow-up examination. Clinical discussion: A lesser omental hernia may occur after colectomy due to iatrogenic disruption of the gastrocolic ligament. This case represented a type II hernia, with the small intestine prolapsing from the retrogastric space through a defect in the lesser omentum. A review of eight post-colectomy cases showed that all were type II. Diagnosis is difficult, but CT findings such as anteriorly displaced, dilated bowel loops and gastric distortion are key. Careful CT evaluation and intraoperative identification are essential for appropriate diagnosis and treatment. Conclusion: A lesser omental hernia can occur after total colectomy. CT imaging is valuable for diagnosis, and surgical intervention is often required.
- 16 September 2026
- Published by Wolters Kluwer Health in International Journal of Surgery Case Reports
- Vol. 138 (10) , 4047-4050
Open AccessA rare case of lesser omental hernia in a male patient following total colectomy
Introduction and importance: A lesser omental hernia is a rare internal hernia in which intestinal loops become entrapped through a defect in the lesser omentum, potentially causing bowel obstruction. Its diagnosis is challenging because of nonspecific symptoms that resemble those of other gastrointestinal diseases. This report presents a case of lesser omental hernia following total colectomy. Case presentation: A 65-year-old male with a history of laparoscopic total colectomy for ulcerative colitis 4 years prior presented with acute abdominal pain and distension. Computed tomography (CT) revealed a closed-loop small-bowel obstruction, leading to emergency surgery. Intraoperatively, no adhesions were found, but nearly the entire small intestine had herniated through a small foramen in the lesser omentum, passing dorsally behind the stomach. The intestine was repositioned, and the foramen was sutured closed. The patient was discharged on postoperative day 15, with no recurrence observed at the 6-month follow-up examination. Clinical discussion: A lesser omental hernia may occur after colectomy due to iatrogenic disruption of the gastrocolic ligament. This case represented a type II hernia, with the small intestine prolapsing from the retrogastric space through a defect in the lesser omentum. A review of eight post-colectomy cases showed that all were type II. Diagnosis is difficult, but CT findings such as anteriorly displaced, dilated bowel loops and gastric distortion are key. Careful CT evaluation and intraoperative identification are essential for appropriate diagnosis and treatment. Conclusion: A lesser omental hernia can occur after total colectomy. CT imaging is valuable for diagnosis, and surgical intervention is often required.
- 7 September 2026
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 15 (4) , 639-645
Neuroendocrine carcinoma in gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)
- 7 September 2026
- Published by Springer Nature in International Cancer Conference Journal
- Vol. 15 (4) , 639-645
Neuroendocrine carcinoma in gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS)
- 29 July 2026
- Published by Springer Nature in Gastric Cancer
- Vol. 29 (5) , 1166-1174
Modified transferrin saturation is associated with postoperative complications in patients undergoing curative gastrectomy for gastric cancer
- 29 July 2026
- Published by Springer Nature in Gastric Cancer
- Vol. 29 (5) , 1166-1174
Modified transferrin saturation is associated with postoperative complications in patients undergoing curative gastrectomy for gastric cancer
- 4 June 2026
- Published by Springer Nature in Clinical Journal of Gastroenterology
Hepatocellular carcinoma in a patient with alcohol-related chronic liver disease with major portosystemic shunt successfully treated with shunt ligation and hepatic resection
A 72-year-old male with a history of heavy alcohol consumption was referred for evaluation and treatment of hepatic lesions. Imaging examinations revealed two masses in liver segments III and VIII, consistent with hepatocellular carcinoma (HCC). Despite normal liver enzyme and tumor marker levels, fasting serum bile acid was markedly elevated (89.7 µmol/L). Contrast-enhanced computed tomography (CT) identified a major portosystemic shunt (PSS) between the left gastric and renal veins. Although the indocyanine green (ICG) retention rate at 15 min was elevated at 51.4%, we attributed the abnormal ICG result to the large PSS rather than cirrhosis. Therefore, partial hepatectomy with shunt ligation was planned. Intraoperative portal pressure remained below 20 cmH₂O both before and after shunt clamping. The patient underwent successful resection and shunt ligation. Postoperatively, liver function normalized, bile acid levels decreased, and ICG retention improved to 12.1%. The patient recovered uneventfully, and follow-up CT at four months showed no recurrence and disappearance of the shunt. This case highlights the importance of intraoperative portal pressure monitoring and functional assessment in patients with major PSS. Shunt ligation can improve hepatic functional reserve and prevent complications such as hepatic encephalopathy. The decision-making process for such cases should integrate preoperative functional assessments with intraoperative hemodynamic findings.
- 4 June 2026
- Published by Springer Nature in Clinical Journal of Gastroenterology
Hepatocellular carcinoma in a patient with alcohol-related chronic liver disease with major portosystemic shunt successfully treated with shunt ligation and hepatic resection
A 72-year-old male with a history of heavy alcohol consumption was referred for evaluation and treatment of hepatic lesions. Imaging examinations revealed two masses in liver segments III and VIII, consistent with hepatocellular carcinoma (HCC). Despite normal liver enzyme and tumor marker levels, fasting serum bile acid was markedly elevated (89.7 µmol/L). Contrast-enhanced computed tomography (CT) identified a major portosystemic shunt (PSS) between the left gastric and renal veins. Although the indocyanine green (ICG) retention rate at 15 min was elevated at 51.4%, we attributed the abnormal ICG result to the large PSS rather than cirrhosis. Therefore, partial hepatectomy with shunt ligation was planned. Intraoperative portal pressure remained below 20 cmH₂O both before and after shunt clamping. The patient underwent successful resection and shunt ligation. Postoperatively, liver function normalized, bile acid levels decreased, and ICG retention improved to 12.1%. The patient recovered uneventfully, and follow-up CT at four months showed no recurrence and disappearance of the shunt. This case highlights the importance of intraoperative portal pressure monitoring and functional assessment in patients with major PSS. Shunt ligation can improve hepatic functional reserve and prevent complications such as hepatic encephalopathy. The decision-making process for such cases should integrate preoperative functional assessments with intraoperative hemodynamic findings.
- 2 June 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (9) , 8090-8091
ASO Author Reflections: Early Tumor Shrinkage: An Early Signal of Benefit From Immune Checkpoint Inhibitors in ESCC
- 2 June 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (9) , 8090-8091
ASO Author Reflections: Early Tumor Shrinkage: An Early Signal of Benefit From Immune Checkpoint Inhibitors in ESCC
- Open Access
- 27 May 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (9) , 8030-8040
Early Tumor Shrinkage and Clinical Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Inhibitors: Real-World Observational Study
Background: Immune checkpoint inhibitors (ICIs) have become a viable treatment method for unresectable or recurrent esophageal squamous cell carcinoma (ESCC). However, the relationships between early tumor shrinkage (ETS) and clinical outcomes for ESCC patients receiving ICIs remain unknown. This observational study investigated the associations between ETS and clinical outcomes for patients with unresectable or recurrent ESCC who received ICIs. Methods: Early tumor shrinkage was defined as the percentage decreases at the first evaluation, and the ETS cutoff value was 20%. Using an unbiased database of 128 unresectable or recurrent ESCC patients who received ICI plus chemotherapy or ICI plus ICI, this study evaluated the relationships between ETS and clinical outcomes by multivariable Cox proportional hazards regression models to adjust for potential confounders, including the clinical and pathologic features. Results: Among the patients, 52% had an ETS of 20% or more, and 48% had an ETS smaller than 20%. The ETS was not significantly associated with any of the clinical or pathologic features examined (all P > 0.09). However, ETS was significantly associated with longer progression-free survival ( P < 0.01). Compared with the ETS-absent group, the multivariable-adjusted hazard ratio (HR) for the ETS-present group was 0.23 (95% confidence interval [Cl], 0.14–0.39; P < 0.01). Similarly, the same trend was observed for overall survival (multivariable-adjusted HR, 0.15; 95% CI, 0.07–0.31; P < 0.01). These prognostic associations of ETS were similarly observed in the ICI+chemotherapy and ICI+ICI groups (all P < 0.01). Conclusions: Early tumor shrinkage was associated with favorable clinical outcomes for ICI-treated patients with unresectable or recurrent ESCC, providing a platform for further investigations of predictive markers and treatment strategies.
- 27 May 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (9) , 8030-8040
Open AccessEarly Tumor Shrinkage and Clinical Outcomes for Esophageal Squamous Cell Carcinoma Patients Treated with Immune Checkpoint Inhibitors: Real-World Observational Study
Background: Immune checkpoint inhibitors (ICIs) have become a viable treatment method for unresectable or recurrent esophageal squamous cell carcinoma (ESCC). However, the relationships between early tumor shrinkage (ETS) and clinical outcomes for ESCC patients receiving ICIs remain unknown. This observational study investigated the associations between ETS and clinical outcomes for patients with unresectable or recurrent ESCC who received ICIs. Methods: Early tumor shrinkage was defined as the percentage decreases at the first evaluation, and the ETS cutoff value was 20%. Using an unbiased database of 128 unresectable or recurrent ESCC patients who received ICI plus chemotherapy or ICI plus ICI, this study evaluated the relationships between ETS and clinical outcomes by multivariable Cox proportional hazards regression models to adjust for potential confounders, including the clinical and pathologic features. Results: Among the patients, 52% had an ETS of 20% or more, and 48% had an ETS smaller than 20%. The ETS was not significantly associated with any of the clinical or pathologic features examined (all P > 0.09). However, ETS was significantly associated with longer progression-free survival ( P < 0.01). Compared with the ETS-absent group, the multivariable-adjusted hazard ratio (HR) for the ETS-present group was 0.23 (95% confidence interval [Cl], 0.14–0.39; P < 0.01). Similarly, the same trend was observed for overall survival (multivariable-adjusted HR, 0.15; 95% CI, 0.07–0.31; P < 0.01). These prognostic associations of ETS were similarly observed in the ICI+chemotherapy and ICI+ICI groups (all P < 0.01). Conclusions: Early tumor shrinkage was associated with favorable clinical outcomes for ICI-treated patients with unresectable or recurrent ESCC, providing a platform for further investigations of predictive markers and treatment strategies.
- 18 May 2026
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 19 (4) , 950-954
A case of long-term survival in unresectable pancreatic cancer with BRCA germline mutation treated with platinum-based chemotherapy
Unresectable pancreatic cancer has the lowest 5 year relative survival rate among all cancers, at approximately 10%. Standard treatments are often limited because of severe toxicities, and therefore long-term treatment is challenging. We report a case of unresectable pancreatic cancer with a BRCA gene mutation achieving long-term survival through modified FOLFIRINOX (mFFX) therapy. A 61-year-old male was diagnosed with unresectable pancreatic head cancer, accompanied by liver metastasis and para-aortic lymph node metastasis. Initial treatment with gemcitabine and nab-paclitaxel resulted in progressive disease, prompting a switch to mFFX. The first evaluation of efficacy showed significant shrinkage of both the primary tumor and metastatic lesions, and the second evaluation confirmed a complete response. After BRCA gene testing became eligible for insurance coverage, a BRCA2 gene mutation was identified. The patient continued treatment with drugs except oxaliplatin. Lung metastasis appeared and was treated with local therapy. Seven years have passed since the start of treatment, and the patient continues to receive treatment without significant side effects. We present a case of unresectable pancreatic cancer with a BRCA germline mutation that was treated with a combination treatment and achieved long-term survival.
- 18 May 2026
- Published by Springer Nature in Clinical Journal of Gastroenterology
- Vol. 19 (4) , 950-954
A case of long-term survival in unresectable pancreatic cancer with BRCA germline mutation treated with platinum-based chemotherapy
Unresectable pancreatic cancer has the lowest 5 year relative survival rate among all cancers, at approximately 10%. Standard treatments are often limited because of severe toxicities, and therefore long-term treatment is challenging. We report a case of unresectable pancreatic cancer with a BRCA gene mutation achieving long-term survival through modified FOLFIRINOX (mFFX) therapy. A 61-year-old male was diagnosed with unresectable pancreatic head cancer, accompanied by liver metastasis and para-aortic lymph node metastasis. Initial treatment with gemcitabine and nab-paclitaxel resulted in progressive disease, prompting a switch to mFFX. The first evaluation of efficacy showed significant shrinkage of both the primary tumor and metastatic lesions, and the second evaluation confirmed a complete response. After BRCA gene testing became eligible for insurance coverage, a BRCA2 gene mutation was identified. The patient continued treatment with drugs except oxaliplatin. Lung metastasis appeared and was treated with local therapy. Seven years have passed since the start of treatment, and the patient continues to receive treatment without significant side effects. We present a case of unresectable pancreatic cancer with a BRCA germline mutation that was treated with a combination treatment and achieved long-term survival.